{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:41:09Z","timestamp":1793868069245,"version":"4.6.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100002918","name":"Copenhagen University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Cardiovascular Academy","award":["Grant number 2022007-HF"],"award-info":[{"award-number":["Grant number 2022007-HF"]}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF20SA0067242"],"award-info":[{"award-number":["NNF20SA0067242"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007405","name":"Danish Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Recent evidence suggest that the lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease (ASCVD) may be observed only in individuals with low-grade systemic inflammation. It was hypothesized that high lipoprotein(a) is a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis irrespective of C-reactive protein levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>A total of 68 090 individuals from the Copenhagen General Population Study, a prospective cohort study, were included. During a median follow-up of 8.1 years, 5104 individuals developed ASCVD, 2432 myocardial infarction, and 1220 aortic valve stenosis. The risk of ASCVD, myocardial infarction, and aortic valve stenosis increased with higher values of both lipoprotein(a) and C-reactive protein. For individuals with lipoprotein(a) in the 91st\u2013100th percentiles (\u226570 mg\/dl, \u2265147 nmol\/l) vs. the 1st\u201333rd percentiles (\u22646 mg\/dl, \u22649 nmol\/l), the multivariable-adjusted hazard ratio for ASCVD was 1.61 (95% confidence interval 1.43\u20131.81) for those with C-reactive protein &amp;lt;2 mg\/l and 1.57 (1.36\u20131.82) for those with C-reactive protein \u22652 mg\/l (P for interaction = 0.87). The corresponding values were 2.08 (1.76\u20132.45) and 1.65 (1.34\u20132.04) for myocardial infarction, and 2.01 (1.59\u20132.55) and 1.73 (1.31\u20132.27) for aortic valve stenosis, respectively (P for interaction = 0.15 and = 0.18). The highest absolute 10-year risks were found in men aged 70\u201379 years with lipoprotein(a) levels in the 91st\u2013100th percentiles and C-reactive protein \u22652 mg\/l, with 34% for ASCVD, 19% for myocardial infarction, and 13% for aortic valve stenosis. The corresponding values in women were 20%, 10%, and 8%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High lipoprotein(a) was a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis independent of C-reactive protein levels.<\/jats:p><\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad055","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T18:22:58Z","timestamp":1677003778000},"page":"1449-1460","source":"Crossref","is-referenced-by-count":80,"title":["Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-3914","authenticated-orcid":false,"given":"Peter E","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Borgmester Ib Juuls Vej 73, 2730 Herlev , Denmark"},{"name":"The Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-1110","authenticated-orcid":false,"given":"Signe","family":"Vedel-Krogh","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Borgmester Ib Juuls Vej 73, 2730 Herlev , Denmark"},{"name":"The Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia R","family":"Kamstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Borgmester Ib Juuls Vej 73, 2730 Herlev , Denmark"},{"name":"The Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Borgmester Ib Juuls Vej 73, 2730 Herlev , Denmark"},{"name":"The Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2023042102570930700_ehad055-B1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: heart disease and stroke statistics\u20132016 update: a report from the American heart association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"2023042102570930700_ehad055-B4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel sirna targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"2023042102570930700_ehad055-B6","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering rna targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2023042102570930700_ehad055-B7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From c-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2023042102570930700_ehad055-B8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity c-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B11","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jacc.2007.07.064","article-title":"Clinical factors, but not c-reactive protein, predict progression of calcific aortic-valve disease: the cardiovascular health study","volume":"50","author":"Novaro","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjcard.2009.10.071","article-title":"Incidence and progression of aortic valve calcium in the multi-ethnic study of atherosclerosis (mesa)","volume":"105","author":"Owens","year":"2010","journal-title":"Am J Cardiol"},{"key":"2023042102570930700_ehad055-B13","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042102570930700_ehad055-B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2018.08.029","article-title":"Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease","volume":"277","author":"Cho","year":"2018","journal-title":"Atherosclerosis"},{"key":"2023042102570930700_ehad055-B15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of c-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023042102570930700_ehad055-B16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity c-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2011.163","article-title":"Index event bias as an explanation for the paradoxes of recurrence risk research","volume":"305","author":"Dahabreh","year":"2011","journal-title":"JAMA"},{"key":"2023042102570930700_ehad055-B18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/eurheartj\/ehab087","article-title":"The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen general population study with 104 046 adults","volume":"42","author":"Holtermann","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B19","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1373\/clinchem.2016.258897","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints\u2014a joint consensus statement from the European atherosclerosis society and European federation of clinical chemistry and laboratory medicine","volume":"62","author":"Nordestgaard","year":"2016","journal-title":"Clin Chemy"},{"key":"2023042102570930700_ehad055-B22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B23","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B24","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"2023042102570930700_ehad055-B25","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0022-2275(20)32100-3","article-title":"Preparation of a stable fresh frozen primary lipoprotein[a] (lp[a]) standard","volume":"40","author":"Kostner","year":"1999","journal-title":"J Lipid Res"},{"key":"2023042102570930700_ehad055-B26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2016.161943","article-title":"Shorter leukocyte telomere length is associated with higher risk of infections: a prospective study of 75,309 individuals from the general population","volume":"102","author":"Helby","year":"2017","journal-title":"Haematologica"},{"key":"2023042102570930700_ehad055-B27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/CLEP.S20247","article-title":"Comparison of Charlson comorbidity index with saps and apache scores for prediction of mortality following intensive care","volume":"3","author":"Christensen","year":"2011","journal-title":"Clin Epidemiol"},{"key":"2023042102570930700_ehad055-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023042102570930700_ehad055-B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2018.12.011","article-title":"The christmas holidays are immediately followed by a period of hypercholesterolemia","volume":"281","author":"Vedel-Krogh","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023042102570930700_ehad055-B30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ijo.2010.137","article-title":"C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization","volume":"35","author":"Timpson","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"2023042102570930700_ehad055-B31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/diacare.26.5.1535","article-title":"C-reactive protein and glycemic control in adults with diabetes","volume":"26","author":"King","year":"2003","journal-title":"Diabetes Care"},{"key":"2023042102570930700_ehad055-B32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2023042102570930700_ehad055-B35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2023042102570930700_ehad055-B36","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies","author":"Harrell FE","year":"2015"},{"key":"2023042102570930700_ehad055-B37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B38","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042102570930700_ehad055-B39","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2021.11.043","article-title":"Lipoprotein(a) and body mass compound the risk of calcific aortic valve disease","volume":"79","author":"Kaltoft","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2023042102570930700_ehad055-B42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacc.2015.05.066","article-title":"Calcification in aortic stenosis: the skeleton key","volume":"66","author":"Pawade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jacbts.2017.03.015","article-title":"Lipoprotein(a) induces human aortic valve interstitial cell calcification","volume":"2","author":"Yu","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"2023042102570930700_ehad055-B44","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/biom9120760","article-title":"Lipoprotein(a) as orchestrator of calcific aortic valve stenosis","volume":"9","author":"Schnitzler","year":"2019","journal-title":"Biomolecules"},{"key":"2023042102570930700_ehad055-B45","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023042102570930700_ehad055-B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yjmcc.2019.05.016","article-title":"Development of calcific aortic valve disease: do we know enough for new clinical trials?","volume":"132","author":"Kostyunin","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"2023042102570930700_ehad055-B47","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated c-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102570930700_ehad055-B50","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023042102570930700_ehad055-B52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"2023042102570930700_ehad055-B53","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1373\/clinchem.2007.098996","article-title":"Ethnic differences in c-reactive protein concentrations","volume":"54","author":"Kelley-Hedgepeth","year":"2008","journal-title":"Clin Chem"},{"key":"2023042102570930700_ehad055-B54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"2023042102570930700_ehad055-B55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the danish national patient registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1449\/50050625\/ehad055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/16\/1449\/50050625\/ehad055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T03:30:59Z","timestamp":1728790259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/16\/1449\/7049152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":55,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad055","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,21]]},"published":{"date-parts":[[2023,2,21]]}}}